You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Researchers identified 34 episignatures that could be used for diagnostic testing and the interpretation of ambiguous genetic test results.
The companies will work together to identify novel biomarkers of the rare genetic disorder Angelman syndrome.
Baylor College of Medicine, Illumina, Aushon Biosystems, SciGene, Invitrogen
Baylor will use the arrays for studying genomic imprinting and its role in developmental diseases.
Quest plans to develop and sell a diagnostic for prostate cancer based on the biomarker.
Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.
A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.
In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.
According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.